Clinical Trial Update: 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for 4SC-202 in combination with pembrolizumab in patients with malignant melanoma who are primary refractory or non-responsive to prior an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• 4SC-202 (null)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: 4SC AG | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED